Page 6 - Malaghan Institute News Today : Breaking News, Live Updates & Top Stories | Vimarsana

<ul> <li>Adding a new CAR co-stimulatory domain (TLR2) to a conventional CD28-costimulated anti-CD19 CAR T-cell reduces cytokine release syndrome- and neurotoxicity-associated cytokines.</li> <li>25 patients with relapsed or refractory B-cell non-Hodgkin lymphomas received CD28/TLR2 co-stimulated anti-CD19 CAR T-cells in a phase 1 dose escalation and expansion trial.</li> <li>No severe CRS and no ICANS neurotoxicity of any grade occurred. Complete responses were seen at doses from 5 &times; 10⁴ to 1 &times; 10⁶ cells/kg.</li> <li>Outpatient therapy and automated manufacture have been established in preparation for a phase 2 trial.</li> </ul>

San diegoUnited statesNew zealandNew zealand generalHunan zhaotaiPeter laiRobert weinkoveWellington zhaotai therapiesMalaghan institute of medical researchThompson family foundationWellington zhaotai therapies limited executive directorZealand ministry of businessAmerican society of hematologyGuangzhou institute of biomedicineMalaghan institute clinicalHealth research council